Exagen

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Earnings

News

Penny Stocks

Small Cap

Markets

Analyst Ratings

Trading Ideas

APDN

HCAT

Wall Street has been hovering around a record high level, which can trigger overvaluation concerns in some investors&#39; minds. This is because investors often opt for the stock-picking approach that involves stocks with a low price-to-earnings (P/E) ratio.

Time to Play 5 Top-Ranked Stocks With Rising P/E?

Pre-Market Outlook

With US futures trading higher this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:


Nike, Tencent Music Entertainment And 3 Stocks To Watch Heading Into Tuesday

Coya Therapeutics’ Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments

Biotech

General

COYA

Houston, Texas-based Coya Therapeutics Inc. (NASDAQ: COYA) has just taken a giant leap in making effective proprietary treatments focused on certain neurodegenerative and autoimmune diseases available to more patients, as it announced the expansion of its exclusive worldwide rights for the development and c

Coya Therapeutics&#39; Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments

Exagen Inc

Press Releases

Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference

Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence

Exagen to Announce Third Quarter 2024 Results on November 12, 2024

Exagen Inc. Reports Third Quarter 2024 Results

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

Health Care

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD

Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

Exagen Inc. to Participate in Upcoming Investor Conferences

Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025

Aadi Bioscience

Achilles Therapeutics plc - American Depositary Shares

Achilles Therapeutics

Agenus

Aligos Therapeutics

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Cibus

CytomX Therapeutics

Forte Biosciences

Gain Therapeutics

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

iBio

IO Biotech

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Kronos Bio

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Mural Oncology

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

OSR Holdings

Quince Therapeutics

Shattuck Labs

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

X4 Pharmaceuticals

Cantor Fitzgerald

Canaccord Genuity

BTIG

Keybanc

Comments

Exagen

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga